Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Graft-versus-host Disease (GvHD)
81%
Acute Myeloid Leukemia
39%
Busulfan
32%
Engraftment
28%
Reduced Intensity Transplantation
26%
Methylenetetrahydrofolate Reductase (MTHFR)
26%
Hematopoietic Stem Cell Transplantation
24%
Stem Cell Transplantation
24%
Hematological Malignancies
22%
Hematopoietic Cell Transplantation
21%
Fludarabine
20%
Myeloablative
20%
Allogeneic
19%
Methotrexate
19%
Reduced Intensity
18%
Transplantation
18%
Unrelated Donor
18%
Antithymocyte Globulin
17%
T Cells
17%
Reduced-intensity Conditioning
17%
Marrow
17%
Complementary DNA (cDNA)
17%
Overall Survival
16%
Cyclophosphamide
16%
Bone Marrow
15%
Graft-versus-leukemia Effect
15%
Conditioning Regimen
15%
Chimerism
14%
Hematopoietic Stem Cell Transplant
13%
Non-myeloablative Transplantation
13%
Nonmyeloablative
13%
Clofarabine
12%
Mini
12%
Phase II Trial
12%
Donor T Cell
12%
Remission
12%
HLA Matching
12%
Allogeneic Transplantation
12%
CD8+ T Cells
12%
Multiple Myeloma
12%
Myeloablative Conditioning
11%
T Cell Response
11%
Leukemia
11%
CD34+
11%
Relapsed or Refractory Acute Myeloid Leukemia
11%
High Risk
11%
Confidence Interval
10%
Mismatched Related Donor
10%
Methotrexate Resistance
10%
Immunology and Microbiology
Graft-Versus-Host Disease
69%
T Cell
51%
Allogeneic Hematopoietic Stem Cell Transplantation
51%
Stem Cell Transplantation
45%
Conditioning
42%
Hematopoietic Cell
39%
Engraftment
35%
Hematopoietic Stem Cell Transplantation
34%
Myeloid
33%
Cell Transplantation
30%
Cyclophosphamide
28%
Chimera
27%
Stem Cell Transplant
23%
Anti-Thymocyte Globulin
19%
Overall Survival
17%
Stem Cell
17%
Acute Graft Versus Host Disease
17%
Dendritic Cell
16%
Methotrexate
16%
Cytotoxic T-Cell
15%
Transplant Procedure
13%
Cytomegalovirus
13%
Immune Reconstitution
12%
Chronic Graft Versus Host Disease
12%
Peripheral Blood Stem Cell
11%
Nonmyeloablative Stem Cell Transplantation
10%
Mouse
10%
Drug Megadose
10%
Short Tandem Repeat
9%
Multiple Myeloma
9%
Immunity
8%
Allogeneic Peripheral Blood Stem Cell Transplantation
7%
Low Drug Dose
6%
Immunosuppression
6%
Plasmacytoid Dendritic Cell
6%
CD34
6%
Real-Time Polymerase Chain Reaction
6%
Next Generation Sequencing
6%
Allograft
6%
Autologous Stem Cell Transplantation
6%
Etanercept
6%
Allogeneic Stem Cell Transplantation
6%
Alloantigen
6%
Granulocyte Colony-Stimulating Factor
5%
Neutrophil
5%
Bone Marrow Cell
5%
Allele
5%
T-Helper Cell
5%
Medicine and Dentistry
Transplantation
52%
Cell Transplantation
36%
Allogeneic Hematopoietic Stem Cell Transplantation
32%
Stem Cell Therapy
31%
Busulfan
30%
Acute Myeloid Leukemia
30%
Hematopoietic Stem Cell Transplantation
30%
Cyclophosphamide
25%
Graft Versus Host Reaction
24%
Stem Cell Transplant
21%
T Cell
17%
Conditioning
17%
Leukemia
17%
Fludarabine
16%
Diseases
16%
Engraftment
16%
Hematologic Malignancy
15%
Thymocyte Antibody
13%
Cladribine
13%
Overall Survival
13%
Peripheral Blood Stem Cell
12%
Myeloablative Conditioning
11%
Multiple Myeloma
11%
Nonmyeloablative Stem Cell Transplantation
10%
Chimera
10%
Acute Graft Versus Host Disease
9%
Clofarabine
9%
Cytomegalovirus
9%
Cytotoxic T-Cell
9%
Melphalan
8%
Allogeneic Stem Cell Transplantation
8%
Progression Free Survival
7%
Chronic Graft Versus Host Disease
7%
Scleroderma
7%
Cyclosporine
7%
Allotransplantation
6%
Whole Body Radiation
6%
Myelodysplastic Syndrome
6%
Systemic Scleroderma
6%
Leukemia Relapse
6%
Reduced Intensity Conditioning
6%
Chronic Myelogenous Leukemia
6%
Immune Reconstitution
6%
Randomized Controlled Trial
6%
Defibrotide
6%
Vein Occlusion
6%
Bronchiolitis Obliterans
6%
Phase II Trials
6%
Acute Myelogenous Leukemia
6%
